Improvement of blood glucose control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of the individual components: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal in the evening. If the dose of metformin hydrochloride needs adjustment, increase the dose gradually.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine is empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current dose of metformin hydrochloride or a therapeutically similar dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching to this medicine from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine should be the patient's existing dose of each component.
No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, treatment with this medicine must be discontinued immediately.
Improvement of blood glucose control in adults with type 2 diabetes
View approved original textHide original text
This medication is administered to enhance blood glucose control in adult patients with type 2 diabetes as an adjunct to diet and exercise. The combination of empagliflozin, sitagliptin, and metformin effectively manages blood glucose levels to assist in diabetes treatment.
How to take
Adult dose
For antidiabetic therapy, the recommended dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of the individual components: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal in the evening. If the dose of metformin hydrochloride needs adjustment, increase the dose gradually.
Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine is empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current dose of metformin hydrochloride or a therapeutically similar dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching to this medicine from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine should be the patient's existing dose of each component.
No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis.
Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, treatment with this medicine must be discontinued immediately.
Precautions
This medication contains three components: sitagliptin, empagliflozin, and metformin hydrochloride.
Firstly, the sitagliptin component may cause severe allergic reactions, albeit rarely. Such reactions can appear within 3 months after starting the medication; if symptoms such as skin rash, difficulty breathing, or swelling of the face or throat occur, you should discontinue the medication immediately and seek medical attention.
Additionally, it may cause acute pancreatitis, an inflammation of the pancreas, so symptoms like abdominal pain, nausea, or vomiting should be observed closely during treatment.
The metformin hydrochloride component may cause lactic acidosis, which is a rare but very serious metabolic disorder. Symptoms can include difficulty breathing, muscle pain, weakness, and abdominal pain. It is particularly advisable for patients with impaired kidney function, liver impairment, severe dehydration, or ongoing infections to avoid this medication.
This drug should not be administered to patients with type 1 diabetes, acute or chronic kidney disorders, acute heart failure, myocardial infarction, or patients scheduled for surgery with severe infections.
Regular kidney function tests should be conducted during treatment, particularly in elderly patients and those with slightly impaired kidney function who may require more frequent monitoring.
There is a risk of hypoglycemia associated with this medication; therefore, caution should be taken for patients on insulin or sulfonylureas to observe symptoms of low blood sugar and respond promptly if they appear.
Moreover, this medication may lead to dehydration or low blood pressure, so intake should be temporarily discontinued and a physician consulted if symptoms such as diarrhea, vomiting, or fever lead to fluid loss.
Increased occurrences of genital infections or urinary tract infections may occur, so prompt treatment is necessary if related symptoms appear.
Caution is advised while driving or operating machinery due to the risk of hypoglycemia, and it is recommended to avoid alcohol consumption during treatment.
The tablets should be swallowed whole and not chewed or crushed; it is normal for the tablet coating to appear in the stool.
It is essential to consult healthcare professionals immediately if any unusual symptoms or discomfort occur during treatment.
Side effects
Severe allergic reactions
anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
dyspepsia
abdominal pain
hyperglycemia
Show 249 moreCollapse
poorly controlled diabetes
genital itching
vulvar pruritus
vaginal infection
weight loss
thirst
rash
vulvodynia
vaginitis
balanitis
other genital infections
urinary tract infections
perineal necrosis
constipation
urticaria
angioedema
increased urination
dysuria
interstitial nephritis
fever
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
ketoacidosis
urosepsis
pyelonephritis
headache
cerebral infarction
intracranial aneurysm
vascular stent stenosis
vascular stent thrombosis
increased alanine aminotransferase
increased aspartate aminotransferase
ureteral stones
acute kidney injury
cervical inflammation
diabetes
hyponatremia
diabetic foot
back pain
glaucoma
pathological myopia
retinal detachment
retinal vein occlusion
macular retinal detachment
limb injuries
road traffic accidents
splenic injury
sternal fracture
angina
Prinzmetal angina
coronary artery disease
deep vein thrombosis
benign neoplasm of the ampulla of Vater
benign ovarian tumor
bladder cancer
gastric cancer
pancreatic carcinoma
rectal cancer
thyroid cancer
uterine leiomyoma
acute cholecystitis
autoimmune hepatitis
cholelithiasis
anxiety
depression
sleep disorders
otalgia
position-related dizziness
dizziness
anemia
lymphadenopathy
hypothyroidism
thyroid nodules
dyspepsia
gastritis
dizziness
chest discomfort
chest pain
weakness
weight loss
vulvar pruritus
genital itching
dyslipidemia
hyperglycemia
back pain
diabetic retinopathy
dry eyes
cough
dyspnea
unstable angina
hypertension
insomnia
taste disturbance
nausea
vomiting
diarrhea
abdominal pain
loss of appetite
erythema
pruritus
urticaria
rash
severe arthralgia with disability
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
severe arthralgia
vesicular pemphigoid
acute renal failure
severe hypoglycemia
severe delayed hypoglycemia
decreased fluid volume
blood glucose ≤ 70 mg/dL
hypoglycemia requiring treatment
vesicles or abrasions
dry mouth
abdominal distension
anal bleeding
chronic gastritis
ischemic colitis
enteritis
bloating
gastric polyps
gingival swelling
passage of bloody stools
hemorrhoids
colon bleeding
pancreatic cysts
rectal pain
dental pain
upper respiratory tract infections
bronchitis
soft tissue infections
chronic sinusitis
gastroenteritis
Helicobacter infection
periodontitis
appendiceal abscess
appendicitis
chronic tonsillitis
conjunctivitis
influenza
laryngitis
tinea corporis
dental abscess
tubo-ovarian abscess
vestibular neuritis
nasopharyngitis
position-related dizziness
sensory impairment
perceptual disturbances
amnestic syndrome
carotid stenosis
diabetic neuropathy
facial paralysis
memory disturbances
neuralgia
Parkinsonism
polyneuropathy
sensory dysfunction
drowsiness
central nervous system-origin dizziness
facial paralysis
drowsiness
fatigue
peripheral edema
facial swelling
peripheral swelling
chills
strange sensations
swelling
pain
pain at the puncture site
ECG abnormalities
decreased hemoglobin
increased hemoglobin
positive Helicobacter test
positive urine erythrocytes
hematuria
overactive bladder
kidney masses
urinary retention
urinary pain
abnormal urination
benign prostatic hyperplasia
erectile dysfunction
atrophic vaginitis
cervical dysplasia
vaginal discharge
hypoglycemia
decreased appetite
somnolence
vitamin D deficiency
dermoid cysts
seborrheic dermatitis
atopic dermatitis
nummular eczema
heat rash
sebaceous gland hyperplasia
lumbar spinal canal stenosis
myalgia
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
pain from fractures
muscle weakness
musculoskeletal pain
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
macular fibrosis
ocular discomfort
conjunctival hyperemia
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
age-related dyspnea
wet cough
allergic rhinitis
residual phlegm
skin lacerations
contusions
rib fractures
concussion
corneal abrasion
falls
hand fractures
ligamentous injury syndrome
open eye injuries
pelvic fractures
arteriosclerosis
diabetic vascular diseases
peripheral artery occlusive disease
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture. The appropriate storage temperature is between 1 to 30 degrees Celsius (33.8 to 86 degrees Fahrenheit). Avoid extremely hot or cold locations and keep it in a cool place away from direct sunlight.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.